Frankfurt - Delayed Quote EUR

Akebia Therapeutics, Inc. (AX9.F)

1.2410

-0.0360

(-2.82%)

At close: 8:03 AM GMT+2

Currency in USD All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

194,623.0000

292,484.0000

211,650.0000

294,644.0000

Cost of Revenue

74,149.0000

85,568.0000

150,671.0000

296,477.0000

Gross Profit

120,474.0000

206,916.0000

60,979.0000

-1,833.0000

Operating Expense

166,549.0000

271,762.0000

325,481.0000

375,993.0000

Operating Income

-46,075.0000

-64,846.0000

-264,502.0000

-377,826.0000

Net Non Operating Interest Income Expense

-6,032.0000

-15,687.0000

-19,936.0000

-8,871.0000

Other Income Expense

182.0000

-13,693.0000

2,414.0000

1,856.0000

Pretax Income

-51,925.0000

-94,226.0000

-282,024.0000

-384,841.0000

Net Income Common Stockholders

-51,925.0000

-94,226.0000

-282,024.0000

-384,841.0000

Diluted NI Available to Com Stockholders

-51,925.0000

-94,226.0000

-282,024.0000

-384,841.0000

Basic EPS

-0.31

-0.28

-0.52

-1.70

-2.78

Diluted EPS

-0.31

-0.28

-0.52

-1.70

-2.78

Basic Average Shares

185,984.0060

187,465.4480

182,782.6800

165,949.6950

138,463.1520

Diluted Average Shares

185,984.0060

187,465.4480

182,782.6800

165,949.6950

138,463.1520

Total Operating Income as Reported

-46,256.0000

-80,779.0000

-264,502.0000

-377,826.0000

Total Expenses

240,698.0000

357,330.0000

476,152.0000

672,470.0000

Net Income from Continuing & Discontinued Operation

-51,925.0000

-94,226.0000

-282,024.0000

-384,841.0000

Normalized Income

-51,220.0000

-77,387.0000

-282,024.0000

-384,841.0000

Interest Income

3,319.0000

Interest Expense

6,032.0000

15,687.0000

19,936.0000

8,871.0000

Net Interest Income

-6,032.0000

-15,687.0000

-19,936.0000

-8,871.0000

EBIT

-45,893.0000

-78,539.0000

-264,502.0000

-377,826.0000

EBITDA

-4,047.0000

-43,259.0000

-228,374.0000

-345,171.0000

Reconciled Cost of Revenue

74,149.0000

85,568.0000

150,671.0000

296,477.0000

Reconciled Depreciation

41,846.0000

35,280.0000

36,128.0000

32,655.0000

Net Income from Continuing Operation Net Minority Interest

-51,925.0000

-94,226.0000

-282,024.0000

-384,841.0000

Total Unusual Items Excluding Goodwill

-705.0000

-16,839.0000

Total Unusual Items

-705.0000

-16,839.0000

Normalized EBITDA

-3,342.0000

-26,420.0000

-228,374.0000

-345,171.0000

12/31/2020 - 4/1/2014

Yahoo Finance Plus Essential access required. Unlock Access

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akebia Therapeutics, Inc. (AX9.F)